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Abstract
Background There is a variation in the administration of antibiotics prophylaxis to reduce the perceived risk of SSI
in patients undergoing non-emergency cholecystectomy. The aim of this study was to determine the effectiveness of
antibiotic prophylaxis following non-emergency cholecystectomy to prevent 30-day superficial surgical site infec-
tions (SSIs) using non-selected, nationally collected, prospective data.
Methods Data were extracted from the CholeS study, which examined and independently validated the outcomes on
consecutive patients following non-emergency cholecystectomy across 166 hospitals in the UK and Ireland. Patients
who received antibiotic prophylaxis were exact matched to those who did not on variables associated with antibiotic
prophylaxis. The primary outcome of interest was superficial SSI, and secondary outcomes included deep SSI,
readmissions, complications and re-interventions within 30 days.
Results Out of a total of 7327 patients included in the study, 4468 (61%) received antibiotic prophylaxis. These were
matched to patients who did not receive antibiotic prophylaxis on a range of demographic and surgical factors,
leaving 1269 pairs of patients for analysis. Within this cohort, patients receiving antibiotic prophylaxis had signif-
icantly lower rates of superficial SSI (0.7% vs. 2.3%, p = 0.001) and all-cause complications (5.8 vs. 8.0%,
p = 0.031), but similar rates of deep SSI (1.0 vs. 1.4%, p = 0.473), readmissions (5.2 vs. 6.2%, p = 0.302) and re-
interventions (2.6 vs. 3.7%, p = 0.093). The number needed to treat to prevent one superficial SSI was 45 (95%
confidence interval 24–662).
Conclusions Antibiotics appear effective at reducing SSI after non-emergency cholecystectomy. However, due to the
high number needed to treat it is unclear whether they provide a worthwhile clinical benefit to patients.
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as Electronic Supplementary Material.
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Introduction
There are wide variations in management of patients
undergoing non-emergency cholecystectomy. One example
is antibiotics prophylaxis administered to reduce the per-
ceived risk of surgical site infections (SSIs) [1, 2]. A recent
systematic review of 19 randomised controlled trials con-
sidered 5259 participants undergoing cholecystectomy for
biliary colic or mild and moderate acute calculous chole-
cystitis. Antibiotic prophylaxis was administered to 2709
(51.5%) patients, and this failed to reduce the risk of SSI or
overall nosocomial infections [3]. Of note, the majority of
studies analysed excluded patients perceived at high risk of
SSI, e.g. converted operations and when intra-operative
cholangiography was performed.
Current guidelines from the USA and the UK do not
recommend antibiotic prophylaxis in non-emergency
cholecystectomy for low- or moderate-risk groups, due to
the low risk of developing SSIs and cost to the health care
system [4–7]. Despite this, between 20 and 80% of patients
undergoing non-emergency cholecystectomy are adminis-
tered antibiotic prophylaxis in nationally collected data sets
[1, 5]. The rationale provided by some clinicians is a per-
ceived increased risk of SSI as a result of intra-operative
contamination with bile, stones or blood and a lack of
pragmatic, effectiveness studies.
The Clinical Variation in Practice of Cholecystectomy
and Surgical Outcomes Study (CholeS study) was a mul-
ticentre prospective, population-based cohort study of
variation in practice of cholecystectomy [8]. It examined
and independently validated the 30-day outcomes on 8914
consecutive patients following both emergency and non-
emergency cholecystectomy across 166 hospitals in the UK
and Ireland between 1 March and 1 May 2014. The main
results of the CholeS study have been recently published
[9–12]. Using this non-selected, validated data of consec-
utive patients, the aim of this study was to determine the
effectiveness of antibiotic prophylaxis following non-
emergency cholecystectomy to prevent 30-day SSI.
Methods
This was a secondary analysis of the CholeS study [8]. The
CholeS study collected anonymous observational data and
did not require research registration as confirmed by the
online National Research Ethics Service (NRES) decision
tool (http://www.hra-decisiontools.org.uk/research/) and
further supported by written confirmation and advice from
the Research and Development Director at University
Hospitals Birmingham NHS Foundation Trust, UK.
The study was registered as a ‘clinical audit’ or ‘service
evaluation’ at each participating hospital under the super-
vision of a named senior investigator (consultant surgeon).
Inclusion and exclusion criteria
The CholeS study-enrolled patients undergoing cholecys-
tectomy for benign gallbladder diseases in acute UK and
Irish hospitals participating in this study between 1 March
and 1 May 2014 were included. This secondary analysis
investigated the group of patients undergoing non-emer-
gency cholecystectomy for benign gallbladder diseases.
Patients undergoing non-emergency cholecystectomy as
delayed operations (defined as a scheduled cholecystec-
tomy following an emergency admission with gallbladder
disease) or elective operations (defined as a planned elec-
tive admission for cholecystectomy referred by their family
doctor and added to the routine surgical waiting list from
the outpatient department with no prior emergency
admission with gallbladder disease) were included. Patients
undergoing an emergency cholecystectomy were thus
excluded. Open, laparoscopic and laparoscopic converted
to open surgeries were included. Patients who had a
cholecystectomy for known gallbladder cancer or as a part
of another surgical procedure, e.g. pancreaticoduodenec-
tomy, bariatric, anti-reflux or transplant operations or an
emergency cholecystectomy (defined as a cholecystectomy
during an acute admission) were excluded.
Outcome measures
The primary outcome of interest was superficial SSI within
30 days. Secondary outcomes included a deep SSI, all-
cause readmissions, all-cause complications, all re-inter-
ventions and post-operative administration of antibiotics
within 30 days. These have been defined previously [9].
Briefly, the following definitions were used:
• Superficial SSI: (1) Purulent drainage from the incision;
OR (2) At least two of: pain or tenderness; localised
swelling; redness; heat; fever; AND. The incision is
opened deliberately to manage infection or the clinician
diagnoses a surgical site infection; OR (3) Wound
organisms AND pus cells from aspirate/swab;
• Deep SSI: (1) A clinical diagnosis of wound infection
with dehiscence of any layer below fat/Scarpa’s fascia;
(2) A clinical diagnosis of intra-abdominal collection
(fever or abdominal pain) with operative or radiological
evidence of a collection;
• Re-interventions: a composite outcome of antibiotics,
radiological drainage, re-laparoscopy, laparotomy.
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Data quality
To standardise data quality, a quality assurance programme
was developed [8]. This included a detailed study protocol,
pilot phase and a requirement for a minimum of 95% data
completeness at submission. Case ascertainment and data
accuracy were further validated by independent investiga-
tors at selected hospitals, who checked data correctness
from 2077 (23.3%) patients against original medical
records. These independent investigators were not involved
in the original data collection. Case ascertainment and
accuracy of collected data were above 95.2 and 99.2%,
respectively.
Explanatory variables
The main explanatory variable was the antibiotic prophy-
laxis, defined as antibiotics administered at induction or
during the operation. Other pre- and peri-operative char-
acteristics were considered as potential explanatory vari-
ables influencing the primary outcomes. A full list
including definitions has been published previously [8].
Briefly, patient characteristics included here were: age, sex,
American Society of Anaesthesiologists (ASA) fitness
grade (1, normal healthy patient; 2, mild systemic dis-
ease;[2, severe systemic disease/severe systemic disease
that is a constant threat to life/moribund patient who is not
expected to survive without the operation), body mass
index (BMI in kg/m2;\24.9, 25.0–29.9, 30.0–34.9,
[35.0), indication [biliary colic, cholecystitis, pancreatitis,
common bile duct (CBD) stones and others]. Surgical
factors considered were grade of operating surgeon (non-
consultant grade; consultant), operative method (laparo-
scopic, converted to open), operative difficulty (as defined
by the Nassar scale of difficulty for cholecystectomy from
1 to 4 [13]) and intra-operative events (bile spilt, stones
spilt, bleeding, bowel Injury, common bile duct injury
(CBD) injury, cholangiogram, CBD explored). In addition,
a composite variable of ‘high-risk’ group for developing an
SSI was generated, including patients aged over 60 years,
undergoing an intra-operative cholangiogram, CBD
exploration, conversion to open, bile spilt, stones spilt,
CBD injury or bowel injury during surgery. These factors
have been identified in guidelines to represent patients at
potential risk of developing a SSI [7]. Low-risk surgery
was considered as patients undergoing surgery with none of
the above risk factors.
Statistical analysis
Initially, univariable analyses were performed to assess the
relationships between antibiotic prophylaxis use, and a range
of patient and surgical factors, as well as patient outcomes.
Continuous variables were compared using independent
samples t tests. Nominal variables were analysed using Chi-
square tests, with Kendall’s tau used for ordinal variables, to
account of the ordering of the categories.
To adjust for factors found to be associated with antibi-
otic prophylaxis, multivariable binary logistic regression
models were produced for each outcome. Antibiotic pro-
phylaxis was entered into the model as a factor, and all of
the other potentially confounding factors were considered
for inclusion, with a forward stepwise entry procedure used
to select independent predictors of outcome.
The data were also analysed using a matched approach.
Patients who received antibiotic prophylaxis were exact
matched to those who did not on all of the confounding
factors considered, with age treated as categorical. The
outcomes were then compared across the resulting pairs of
patients using McNemar’s test, and odds ratios (OR) with
95% confidence interval (CI) were produced, in order to
compare the results to those of the multivariable analysis
for consistency.
Finally, to test whether the effect of antibiotic prophy-
laxis differed by patient risk, an additional set of multi-
variable binary logistic regression models were produced.
The patient risk group, antibiotic prophylaxis and the
interaction term were entered into the model. One model
included the whole cohort of patients, so confounding
factors were added to the model using a forward stepwise
approach, to give adjusted odds ratios. The analysis was
also repeated for the subgroup of matched patients, which
did not require this adjustment. The significance of the
interaction terms was from these models which were
interpreted as testing the difference in the effectiveness of
antibiotic prophylaxis in the low- and high-risk groups.
All analyses were performed using IBM SPSS 22 (IBM
Corp. Armonk, NY). Patients with missing data were
excluded on a per-analysis basis, and p\ 0.05 was deemed
to be indicative of statistical significant throughout.
Results
Study cohort
Data were collected on 8914 patients undergoing a chole-
cystectomy between 1 March 2014 and 1 May 2014. Of
these, 7400 (83.0%) patients underwent non-emergency
cholecystectomy. Antibiotic prophylaxis data were
unavailable in 73 cases, which were excluded, leaving
7327 cases for analysis. General patient demographics are
presented in Table 1. Patients were predominantly female
(n = 5482, 74.8%) and had a mean age of 51.1 years
(SD = 16.3), and antibiotic prophylaxis was administered
in 4468 (61.0%) cholecystectomies.
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Antibiotic prophylaxis use
Patients receiving antibiotic prophylaxis were significantly
older and more likely to be male, to have a delayed
admission, be operated on by a consultant, have surgeries
converted to open and to have greater ASA and operative
difficulty (Table 1). Antibiotic prophylaxis also differed
significantly by primary indication, being most commonly
Table 1 Patient characteristics
All patients
(n = 7327)
No antibiotic prophylaxis
(n = 2859)
Antibiotic prophylaxis
(n = 4468)
P value
Age (years) Mean (SD) 51.1 (16.3) 49.5 (16.0) 52.1 (16.4) \0.001
Gender Female 5482 (74.8%) 2288 (80.0%) 3194 (71.5%) \0.001
Male 1845 (25.2%) 571 (20.0%) 1274 (28.5%)
BMI \25 1492 (21.2%) 606 (21.7%) 886 (20.8%) 0.217
25.1–30.0 2506 (35.6%) 1013 (36.2%) 1493 (35.1%)
30.1–35.0 1718 (24.4%) 647 (23.1%) 1071 (25.2%)
[35.0 1333 (18.9%) 529 (18.9%) 804 (18.9%)
ASA grade 1 2844 (39.1%) 1259 (44.3%) 1585 (35.7%) \0.001
2 3741 (51.4%) 1370 (48.3%) 2371 (53.4%)
[2 692 (9.5%) 210 (7.4%) 482 (10.9%)
Indication Colic 4326 (59.1%) 1900 (66.5%) 2426 (54.3%) \0.001
Cholecystitis 1753 (23.9%) 529 (18.5%) 1224 (27.4%)
Pancreatitis 579 (7.9%) 192 (6.7%) 387 (8.7%)
CBD stone 483 (6.6%) 148 (5.2%) 335 (7.5%)
Other 182 (2.5%) 87 (3.0%) 95 (2.1%)
Admission type Elective 4095 (55.9%) 1800 (63.0%) 2295 (51.4%) \0.001
Delayed 3232 (44.1%) 1059 (37.0%) 2173 (48.6%)
Grade of operating surgeon Non-consultant 1516 (20.7%) 659 (23.1%) 857 (19.2%) \0.001
Consultant 5808 (79.3%) 2198 (76.9%) 3610 (80.8%)
Operative method Laparoscopic 7109 (97.0%) 2834 (99.1%) 4275 (95.7%) \0.001
Converted to open 218 (3.0%) 25 (0.9%) 193 (4.3%)
Nassar operative 1 3149 (43.2%) 1550 (54.7%) 1599 (36.0%) \0.001
Difficulty 2 2248 (30.9%) 854 (30.1%) 1394 (31.4%)
3 1365 (18.7%) 369 (13.0%) 996 (22.4%)
4 519 (7.1%) 62 (2.2%) 457 (10.3%)
Bile spilt Yes 1866 (25.6%) 342 (12.1%) 1524 (34.2%) \0.001
No 5416 (74.4%) 2483 (87.9%) 2933 (65.8%)
Stones spilt Yes 616 (8.5%) 85 (3.0%) 531 (11.9%) \0.001
No 6656 (91.5%) 2739 (97.0%) 3917 (88.1%)
Bleeding Yes 548 (7.5%) 140 (5.0%) 408 (9.2%) \0.001
No 6724 (92.5%) 2686 (95.0%) 4038 (90.8%)
Bowel injury Yes 39 (0.5%) 7 (0.2%) 32 (0.7%) \0.001
No 7229 (99.5%) 2816 (99.8%) 4413 (99.3%)
CBD injury Yes 18 (0.2%) 0 (0.0%) 18 (0.4%) \0.001
No 7192 (99.8%) 2771 (100.0%) 4421 (99.6%)
IOC Yes 737 (10.1%) 209 (7.4%) 528 (11.9%) \0.001
No 6541 (89.9%) 2617 (92.6%) 3924 (88.1%)
CBD explored Yes 162 (2.2%) 30 (1.1%) 132 (3.0%) \0.001
No 7110 (97.8%) 2793 (98.9%) 4317 (97.0%)
p Values between antibiotics prophylaxis and no antibiotic prophylaxis groups are from Chi-square tests for nominal variables, Kendall’s tau for
ordinal variables and t tests for continuous variables; SD standard deviation, BMI body mass index, ASA American Society of Anaesthesiologists;
CBD common bile duct, IOC intra-operative cholangiogram
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used in patients with previous cholecystitis and least
common in those with biliary colic or ‘other’ indications
(Table 1). All the intra-operative events (bile spilt, stones
spilt, bleeding, bowel Injury, CBD injury, cholangiogram,
CBD explored) were associated with significantly
increased likelihood of antibiotic prophylaxis usage
(Table 1).
Outcomes at 30 days
The numbers of patients at 30 days with a superficial SSI
was 147 (2.0%), deep SSI 140 (1.9%), all-cause compli-
cations 714 (9.7%), post-operative antibiotics use 389
(5.3%) and re-interventions 416 (5.7%). Patients receiving
antibiotic prophylaxis were observed to have significantly
higher rates of all-cause complications, re-interventions
and the requirement for post-operative antibiotics
(Table 2). However, this analysis did not account for the
significant selection bias in the antibiotic prophylaxis that
was previously identified.
In order to account for the effect of selection bias, a set
of multivariable analyses were performed to test the impact
of antibiotic prophylaxis, after accounting for all of pre-
and peri-operative factors in Table 1. The adjusted odds
ratios from these analyses are reported in Table 3, and full
details of the models are reported in Supplementary
Tables 1–6. This analysis found superficial SSI to be sig-
nificantly less likely when antibiotic prophylaxis was
administered (OR 0.54, 95% CI 0.37–0.78, p = 0.001). No
significant association was detected between antibiotic
prophylaxis and all-cause readmission, complications, deep
SSI or re-interventions.
Matched study
A paired matched approach was also used to further
understand the effect of antibiotic prophylaxis. A total of
1269 pairs of patients could be successfully matched on all
of the factors in Table 1 and were included in the analysis.
Supplementary Table 7 shows a comparison of patients
included in the paired analysis to the remainder of the
cohort. The rates of the outcomes being considered were
then compared between these two groups (Table 4).
Patients receiving antibiotic prophylaxis again had signif-
icantly lower rates of superficial SSI (p = 0.001), with an
odds ratio similar to that from the multivariable analysis
(OR 0.30, 95% CI 0.13–0.68, p = 0.001). Of patients
treated with antibiotic prophylaxis, 0.7% developed SSI,
Table 2 Univariable analysis of outcomes
No antibiotic prophylaxis
(n = 2859)
Antibiotic prophylaxis
(n = 4468)
P value
Superficial SSI 61 (2.1%) 86 (1.9%) 0.550
Deep SSI 38 (1.3%) 102 (2.3%) 0.004
All-cause readmissions 182 (6.4%) 300 (6.7%) 0.595
All-cause complications 236 (8.3%) 478 (10.7%) \0.001
All re-interventionsa 126 (4.4%) 290 (6.5%) \0.001
Post-operative antibiotics 118 (4.1%) 271 (6.1%) \0.001
p Values from Chi-square tests
a Composite outcome combining post-operative antibiotics, radiological drainage, re-laparoscopy and laparotomy
SSI surgical site infection
Table 3 Multivariable analyses of outcomes
Adjusted odds ratio
(95% CI)
P value
Superficial SSI 0.54 (0.37–0.78) 0.001
Deep SSI 1.12 (0.73–1.71) 0.616
All-cause readmissions 0.87 (0.71–1.07) 0.188
All-cause complications 0.92 (0.77–1.11) 0.395
All re-interventionsa 0.92 (0.72–1.17) 0.479
Post-operative antibiotics 0.88 (0.69–1.13) 0.328
Odds ratios and p values from multivariable binary logistic regression models
a Composite outcome combining post-operative antibiotics, radiological drainage, re-laparoscopy and laparotomy
SSI surgical site infection
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compared to 2.3% in the non-prophylaxis group, giving a
number needed to treat (NNT) to prevent one SSI of 63
(95% CI 44–176). The paired analysis also found antibiotic
prophylaxis to be associated with a significantly reduced
rate of all-cause complications, with an odds ratio of 0.71
(95% CI 0.54–0.98, p = 0.031), giving a NNT of 45 (95%
CI 24–662). The results of the two statistical approaches
are reported graphically in Fig. 1.
An additional analysis was performed to test whether the
effectiveness antibiotic prophylaxis differed by low-risk
(46.7%) or high-risk (53.3%) patients for a SSI (Fig. 2).
The effectiveness of antibiotic prophylaxis to reduce
Table 4 Matched analysis
No antibiotic prophylaxis
(n = 1269)
Antibiotic prophylaxis
(n = 1269)
Odds ratio
(95% CI)
P value
Superficial SSI 29 (2.3%) 9 (0.7%) 0.30 (0.13–0.68) 0.001
Deep SSI 18 (1.4%) 12 (1.0%) 0.72 (0.33–1.55) 0.473
All-cause readmissions 79 (6.2%) 66 (5.2%) 0.83 (0.58–1.17) 0.302
All-cause complications 102 (8.0%) 74 (5.8%) 0.71 (0.54–0.98) 0.031
All re-interventionsa 49 (3.9%) 33 (2.6%) 0.67 (0.42–1.06) 0.093
Post-operative antibiotics 47 (3.7%) 32 (2.5%) 0.67 (0.43–1.06) 0.110
p values from McNemar’s test
a Composite outcome combining post-operative antibiotics, radiological drainage, re-laparoscopy and laparotomy
SSI surgical site infection
Fig. 1 Relationship between
antibiotic prophylaxis and
outcomes in the multivariable
and paired analyses
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superficial SSI did not differ significantly between the
groups in either the multivariable (low risk: OR 0.56, 95%
CI 0.33–0.96 vs. high risk: 0.55, 0.33–0.94) or matched
(0.26, 0.11–0.64 vs. 0.47, 0.12–0.91) analyses, with
p = 0.666 and 0.481, respectively.
Discussion
This study used validated, non-selected population-level
data collected as part of the CholeS study [9–12]. In this
cohort, 61% of patients undergoing non-emergency
cholecystectomy were administered antibiotic prophylaxis.
When factors accounting for antibiotic prophylaxis use
were adjusted for, antibiotic prophylaxis appeared to
reduce superficial SSI at 30 days. This effect was still seen
when patients were matched 1-to-1 based on factors related
to antibiotic prophylaxis use and did not differ significantly
between low- and high-risk patients. There was no evi-
dence antibiotic prophylaxis significantly reduced the rates
of deep SSIs, readmissions, post-operative antibiotic use or
re-interventions at 30 days.
Evidence from randomised studies and meta-
analyses
The results of this study differ from the current body of
evidence of antibiotic prophylaxis in non-emergency chole-
cystectomy. The majority of randomised studies have showed
a small, but non-statistically significant decrease in infective
complications when antibiotic prophylaxis is administered.
These studies also failed to show a difference in overall SSI
rates [3]. The only positive randomised trial showed a sig-
nificant 2% reduction in SSI with antibiotic prophylaxis using
a superiority design [14]. A further non-inferiority ran-
domised trial, which included patients at moderate to high
risk of SSI, demonstrated no difference in the antibiotic
prophylaxis group using a non-inferiority margin of 11% for
the overall infection rate [15]. Taken together with the find-
ings from this study, it does suggest antibiotic prophylaxis
reduces certain infective complications.
Two recent meta-analyses have been published com-
paring the effectiveness of antibiotic prophylaxis in non-
emergency cholecystectomy. SSIs were detected in 2.4%
of patients given antibiotic prophylaxis and 3.2% who
were not [3]. This was however not statistically signifi-
cant. Another meta-analysis was conducted on 21 trials
and 5207 patients who underwent non-emergency chole-
cystectomy [16]. This found antibiotic usage to signifi-
cantly reduce the rate of SSI, from 4.0 to 2.6%. However,
this 1.4% absolute risk reduction means 70 patients would
be needed to be given antibiotic prophylaxis to prevent 1
SSI.
Population-based series have also been analysed. The
Swedish Register of Gallstone Surgery and ERCP (Gall-
Riks) study analysed 10,927 patients and found a para-
doxical increase in infective complications in the patients
given prophylactic antibiotics. This effect was diminished
when the results were adjusted for confounding factors,
such as age, indication, conversion to open surgery, oper-
ative time and gallbladder perforation [1]. The authors
concluded that prophylactic antibiotics were unnecessary
during non-emergency cholecystectomy, and this has
become a quality metric in Sweden.
Fig. 2 Interaction between
antibiotic prophylaxis and
patient risk of superficial
surgical site infection
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The results derived from the CholeS study again show
an increase in complications in non-adjusted outcomes.
Outcomes were then adjusted for patient and surgical fac-
tors that influence the administration of antibiotic prophy-
laxis. In addition, a 1-to-1 paired analysis was performed,
where patients were identically matched such that the only
difference between the groups was the administration of
antibiotic prophylaxis. Antibiotic prophylaxis reduced the
rate of superficial SSI from 2.3 to 0.7%, an effect size that
was consistent with the analysis that used multivariable
adjustment on the whole cohort. This produced a NNT of
63 and 45 in the multivariable adjusted and matched
analyses, respectively. This may reflect the inclusion of
higher risk and unselected patients in the CholeS study
compared to the randomised studies. Even in this analysis,
the effectiveness of prophylactic antibiotics remains small.
Interpretation of our results
One explanation for the differences between our results and
current evidence is the lack of studies assessing the effect of
antibiotic prophylaxis in high-risk groups. The most recent
guidelines from both the UK and the USA suggest antibiotic
prophylaxis, but state that it should be considered in groups
at high risk of SSI, such as having an intra-operative
cholangiogram, bile spillage or conversion to open surgery
[7]. However, when the CholeS cohort was divided into
high- (53.3%) and low-(46.7%) risk groups, antibiotic pro-
phylaxis was found to be similarly effective at reducing the
incidence of superficial SSI, regardless of patient risk.
Antibiotics’ side effects
Benign gallbladder disease is a major global health burden
with an estimated 115 patients for every 100,000 of the
world’s population undergoing a cholecystectomy for
benign gallbladder disease every year [17]. There is a cur-
rent global campaign to improve awareness of antibiotic
stewardship. One strategy is to reduce inappropriate antibi-
otic administration, which in part will help address the issue
of emerging resistance. In addition, complications of
antibiotic use include anaphylaxis, rash and nosocomial
infections (e.g. Clostridium difficile), and the additional cost
must also be considered. The current studies investigating
antibiotic prophylaxis have not been powered to investigate
antibiotic-related adverse events or cost effectiveness.
Available data is limited and inconclusive on the real burden
of adverse reactions [3, 14]. One large study of the use of
antibiotic prophylaxis estimated an incidence of Clostridium
difficile of up to 1.7% depending upon type of antibiotic,
leading to a number needed to harm 1 in 91 [18]. The risks
and costs of antibiotic prophylaxis must be balanced against
the cost of an SSI, which incurs a cost of up to £3500 in the
UK [19]. This has led some to suggest antibiotic prophylaxis
should be simply administered during all types of surgeries,
even when there is a low risk of SSI [20].
Study limitations
There are limitations to this study. The data represents a
two-month ‘snap-shot’ of practice and may not have fully
captured all complications requiring a family doctor
attendance. However, it is likely that the proportion of
these events is similar in both groups.
In addition, this study prospectively collected and inde-
pendently validated data obtained utilising trainee-led net-
works in the UK and Ireland. This methodology is powerful
and accurate when studying surgical outcomes [21, 22].
Data were not collected on antibiotic type, as this was
left to the discretion of the operating surgeon and guided by
local hospital policy. Also, it is unknown whether antibi-
otics were given pre-operatively, for instance in a difficult
case, or intra-operatively, for instance when bile or stones
are spilled. In the former case, the use of antibiotics is
confounded by neither patients nor disease characteristics,
while in the latter the administration of antibiotics is cau-
sative. This makes it difficult to interpret the association
between antibiotics and infections, and suggests that fur-
ther research is needed in high-risk patients.
Conclusions
Despite the current evidence, 61% of the patients in the
CholeS data set were administered antibiotic prophylaxis,
which is consistent with other population data sets. When
factors accounting for antibiotic prophylaxis use were
accounted for, either using multivariable adjustment or
matched analyses, antibiotic prophylaxis appeared to
reduce superficial SSI at 30 days. There was no evidence
antibiotic prophylaxis significantly reduced the rates of
deep SSIs, readmissions, post-operative antibiotic use or
re-interventions at 30 days. The results of this study sug-
gest the need for a high-quality, pragmatic, randomised
controlled trial looking at the potential benefit of antibiotic
prophylaxis, particularly in high-risk patients.
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